AVEO Pharmaceuticals (NASDAQ:AVEO) and Bellicum Pharmaceuticals (NASDAQ:BLCM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.
Insider & Institutional Ownership
29.6% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.2% of Bellicum Pharmaceuticals shares are owned by institutional investors. 3.8% of AVEO Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Bellicum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
AVEO Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Bellicum Pharmaceuticals has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
This is a breakdown of recent recommendations for AVEO Pharmaceuticals and Bellicum Pharmaceuticals, as provided by MarketBeat.
||Strong Buy Ratings
AVEO Pharmaceuticals currently has a consensus price target of $2.55, suggesting a potential upside of 157.21%. Given AVEO Pharmaceuticals’ higher possible upside, equities research analysts clearly believe AVEO Pharmaceuticals is more favorable than Bellicum Pharmaceuticals.
Valuation and Earnings
This table compares AVEO Pharmaceuticals and Bellicum Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
AVEO Pharmaceuticals has higher revenue and earnings than Bellicum Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than Bellicum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares AVEO Pharmaceuticals and Bellicum Pharmaceuticals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
AVEO Pharmaceuticals beats Bellicum Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.